A patient with an extremely rare genetic form of Turner syndrome (45, X/46, XX/47, XXX karyotype) developed severe bone weakness and repeated fractures due to hormone imbalances. According to Gram Research analysis, treatment with denosumab injections every six months combined with calcium and vitamin D supplements prevented new fractures for nine months. This rare condition affects fewer than 30 documented cases worldwide, typically appearing in young adults with hormone deficiencies.
A case report from a major Chinese hospital describes a patient with a rare form of Turner syndrome, a genetic condition affecting sex chromosomes. The patient experienced repeated bone fractures and weak bones (osteoporosis) due to hormone imbalances. According to Gram Research analysis of this case and 26 similar cases worldwide, this condition typically appears in young adults and requires specialized treatment. The patient improved significantly after receiving bone-strengthening medications including denosumab injections combined with calcium and vitamin D supplements, with no new fractures occurring over nine months of treatment.
Key Statistics
A case report from Peking Union Medical College Hospital in 2025 documented one patient with the rare 45, X/46, XX/47, XXX mosaic Turner syndrome karyotype who experienced no new fractures during nine months of treatment with denosumab injections combined with calcium and vitamin D supplements.
A literature review identified only 26 cases worldwide with complete clinical data for the 45, X/46, XX/47, XXX mosaic Turner syndrome karyotype, with a median diagnosis age of 20.5 years, showing this is an extremely rare genetic condition.
Among 26 documented cases of this rare genetic variation, patients diagnosed before age 18 predominantly presented with short stature, while patients over 40 years old frequently developed serious systemic diseases including hearing impairment, psychiatric disorders, seizures, and blood cancers.
The Quick Take
- What they studied: How a rare genetic condition called mosaic Turner syndrome causes weak bones and repeated fractures, and whether bone-strengthening medications can help prevent future breaks.
- Who participated: One patient with a very rare genetic variation (45, X/46, XX/47, XXX karyotype) who had Turner syndrome, plus a review of 26 similar cases reported worldwide.
- Key finding: A patient with this rare genetic condition developed severe bone weakness and multiple fractures. After receiving denosumab injections every six months plus calcium and vitamin D supplements, the patient had no new fractures during nine months of follow-up treatment.
- What it means for you: This case shows that people with rare genetic conditions affecting sex hormones can develop weak bones, but targeted medical treatment can effectively prevent fractures. However, this is an extremely rare condition affecting very few people worldwide.
The Research Details
This is a case report, which means doctors documented the medical history and treatment of one specific patient with an extremely rare genetic condition. The patient had Turner syndrome, a condition where a person’s sex chromosomes are abnormal. In this case, the patient had three different chromosome patterns in different cells of the body (called mosaicism). The doctors performed bone density scans and spinal X-rays to diagnose osteoporosis (weak bones) and tracked the patient’s response to treatment over nine months. The researchers also reviewed medical literature to find 26 other cases worldwide with the same rare genetic pattern, allowing them to describe how this condition typically develops at different ages.
Case reports are valuable for documenting rare conditions that affect very few people. Because this genetic variation is so uncommon, researchers cannot easily conduct large studies. By carefully documenting one patient’s experience and comparing it to other reported cases, doctors can learn how to recognize and treat this condition in future patients. This helps build medical knowledge about rare genetic disorders.
This is a single case report, which is the lowest level of scientific evidence. However, the diagnosis was confirmed with genetic testing (karyotype analysis) and bone imaging, making it reliable for this specific patient. The inclusion of a literature review examining 26 similar cases adds context and helps show whether this patient’s experience is typical. The nine-month follow-up period is relatively short for assessing long-term outcomes.
What the Results Show
The patient presented with primary amenorrhea (never having a menstrual period) and a history of repeated bone fractures. Bone density scans confirmed osteoporosis (significantly weakened bones), and spinal X-rays showed multiple wedge-shaped deformities in the vertebrae (spine bones). Blood tests revealed abnormally high levels of hormones that stimulate the sex glands (hypergonadotropic hypogonadism), indicating the body’s reproductive system was not functioning properly. Genetic testing confirmed the rare karyotype of 45, X/46, XX/47, XXX, meaning different cells in the body had different numbers of sex chromosomes. After starting treatment with denosumab (a bone-strengthening injection given every six months) combined with calcium and vitamin D supplements, the patient experienced no new fractures during the nine-month follow-up period. This suggests the treatment was effective at preventing further bone damage.
The literature review of 26 other cases with the same rare genetic pattern revealed important patterns based on age at diagnosis. Patients diagnosed before age 18 typically presented with short stature (being significantly shorter than average). Patients of reproductive age sometimes experienced infertility but could achieve pregnancy with assisted reproductive technology (fertility treatments). Patients over 40 years old frequently developed other serious health conditions including hearing loss, psychiatric disorders, seizures, ovarian tumors, multiple myeloma (a type of blood cancer), and sideroblastic anemia (a blood disorder affecting red blood cell production).
This case adds to a small but growing body of medical literature on this extremely rare genetic variation. The median age at diagnosis across all 26 reported cases was 20.5 years, suggesting this condition is often discovered during young adulthood. The patient’s presentation with bone fractures and hormone imbalance fits the expected pattern for this condition. The successful treatment response to denosumab and calcium/vitamin D supplementation aligns with standard osteoporosis management but has rarely been documented in this specific genetic condition.
This is a single case report, so the findings apply only to this one patient and cannot be generalized to all people with this condition. The follow-up period of nine months is relatively short for assessing long-term bone health and fracture prevention. The case report does not include a control group for comparison. Because this genetic variation is so rare (only 26 cases reported worldwide), it is impossible to conduct large-scale studies. The treatment response in this patient may not be identical to how other patients would respond.
The Bottom Line
People diagnosed with this rare genetic condition should work with endocrinologists (hormone specialists) and bone health experts to monitor bone density and prevent fractures. Treatment with bone-strengthening medications like denosumab combined with calcium and vitamin D supplementation appears effective based on this case, though more research is needed. Regular bone density screening and spinal imaging are important for early detection of bone problems. Moderate confidence: This recommendation is based on one case and clinical experience, not large-scale studies.
This information is primarily relevant to the extremely small number of people worldwide with this specific rare genetic variation of Turner syndrome. Healthcare providers caring for patients with Turner syndrome or other rare sex chromosome disorders should be aware of the bone health risks. People with Turner syndrome who experience repeated fractures should be evaluated for osteoporosis. This does not apply to people without Turner syndrome or related genetic conditions.
Based on this case, bone-strengthening treatment appears to show benefits within the first nine months, with the patient experiencing no new fractures during this period. However, long-term benefits beyond nine months are unknown. Bone density improvements typically take 12 to 24 months to become apparent on imaging studies.
Frequently Asked Questions
What is mosaic Turner syndrome and how does it cause weak bones?
Mosaic Turner syndrome is a rare genetic condition where different cells in the body have different numbers of sex chromosomes. This causes hormone imbalances that prevent the body from maintaining strong bones, leading to osteoporosis and fractures. Only 26 cases of this specific genetic pattern have been reported worldwide.
Can denosumab prevent fractures in people with Turner syndrome?
One documented case showed that denosumab injections every six months, combined with calcium and vitamin D supplements, prevented new fractures for nine months. However, this is based on a single patient, and more research is needed to confirm effectiveness in other patients with this rare condition.
At what age do people typically get diagnosed with this rare genetic condition?
The median diagnosis age across 26 reported cases is 20.5 years. Younger patients (under 18) typically present with short stature, while older patients (over 40) often develop additional serious health conditions like hearing loss, seizures, and blood disorders.
How rare is the 45, X/46, XX/47, XXX karyotype?
This genetic variation is extremely rare, with only 26 cases with complete clinical information reported worldwide as of 2025. It represents a very small subset of Turner syndrome cases and affects fewer people than other genetic conditions.
What other health problems do people with this genetic condition experience?
Patients over 40 years old frequently develop hearing impairment, psychiatric disorders, seizures, ovarian tumors, multiple myeloma, and sideroblastic anemia. Younger patients may experience infertility, though some achieve pregnancy with fertility treatments.
Want to Apply This Research?
- Users with Turner syndrome or similar conditions should track bone health metrics including bone density scan results (DEXA scores), number of fractures or falls, medication adherence for calcium and vitamin D supplements, and denosumab injection dates. Record any new fractures or bone pain immediately.
- Set reminders for daily calcium and vitamin D supplementation, schedule denosumab injections every six months, and maintain a log of any falls or injuries. Users should also track physical activity, as weight-bearing exercise supports bone health.
- Schedule bone density scans annually or as recommended by your doctor. Track fracture history and medication compliance monthly. Monitor hormone levels through regular blood work as directed by your endocrinologist. Use the app to maintain a timeline of all bone-related health events and treatment responses.
This article describes an extremely rare genetic condition documented in only 26 cases worldwide. The information is for educational purposes and should not replace professional medical advice. If you have Turner syndrome, a family history of sex chromosome disorders, unexplained bone fractures, or amenorrhea, consult with an endocrinologist or genetic specialist. Treatment decisions should be made in consultation with qualified healthcare providers who can evaluate your individual medical situation. This case report describes one patient’s experience and may not apply to others with similar conditions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.